drugset / Trial / NCT04890236
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Phase 0
Completed
4 enrolled
Emory University
National Cancer Institute (NCI) · collabNovartis · collabSecura Bio, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This early phase I trial investigates how well duvelisib exposure before CAR-T cell manufacturing works to enhance immune profiles of T cells in patients with diffuse large B-cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Duvelisib, an oral phosphoinositide 3-kinase (PI3K) inhibitor, may favorably change a patient's T cells to make them more efficient and have a longer duration for manufacturing of CAR-T cells.
Timeline
- Start
- 2022-01-13
- Primary completion
- 2024-03-20
- Completion
- 2024-09-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Duvelisib | Small molecule | — | Oral |
| Subject | Tisagenlecleucel | Cell therapy | — | Other |